May 18, 2022 -- Forge Biologics has created its new Scientific and Manufacturing Advisory Board (SMAB) filled with leaders in the field of gene therapy development and manufacturing. This independent panel represents Forge’s commitment to enhancing its gene therapy offerings through insights from experts in the field.
Among Forge's SMAB members, Steven Gray, PhD, provides expertise in adeno-associated viral (AAV) gene therapy vector engineering. Gray focuses on optimizing gene delivery into the nervous system utilizing AAV-based treatments and currently serves as the director of the University of Texas Southwestern (UTSW) Viral Vector Facility.
Robert Kotin, PhD, offers expertise in AAV gene therapy manufacturing, emphasized by his baculovirus-based AAV production system. Kotin has also headed the AAV gene therapy program at Genetic Therapy and served as a senior investigator and laboratory chief within the National Institutes of Health.
Karen Kozarsky, PhD, brings over 25 years of experience in gene therapy development to SMAB, focusing on AAV-based gene therapies for treating rare inherited disease. Furthermore, Kozarsky served as president of Vector BioPartners and a head of gene therapy within GlaxoSmithKline.
Haiyan Ma, PhD, possesses 30 years of laboratory, pharmaceutical, and research experience, with a background in molecular biology, cell and gene therapy application, virology, and DNA/RNA/protein bioanalysis. Additionally, Ma has led the establishment of a good laboratory practice compliant molecular biology lab.
Finally, Simon Waddington, PhD, contributes his research knowledge of viral and non-viral gene therapies. Waddington has been published in Cell, Nature Medicine, and Science Translational Medicine due to his work on AAV and lentivirus biology.